Anti-PD1 in combination with an inhibitor of PCSK9 to increase MHC class I molecule expression on tumor cells as immunotherapy for NSCLC
Administered By
Awarded By
Contributors
- Antonia, Scott Joseph Principal Investigator
- Kelley, Michael John Co Investigator
- Nixon, Andrew Benjamin Co Investigator
- Owzar, Kouros Director
- Shi, Pixu Biostatistician
- Wang, Xiaofei Biostatistician
- Weinhold, Kent James Laboratory Director
Start/End
- June 15, 2021 - June 14, 2024